[HTML][HTML] JAK inhibitors in rheumatology: implications for paediatric syndromes?
SA Kerrigan, IB McInnes - Current rheumatology reports, 2018 - Springer
SA Kerrigan, IB McInnes
Current rheumatology reports, 2018•SpringerAbstract Purpose of Review Given the recent increase in the profile and use of Janus kinase
inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the
current evidence accruing for use in paediatric rheumatology patients. Recent Findings
Significant advances have been made in the management of rheumatic diseases in the past
two decades. The introduction of biologic agents in both adults and children has provided
significant improvements to patient outcomes and led to better quality of life. Moreover …
inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the
current evidence accruing for use in paediatric rheumatology patients. Recent Findings
Significant advances have been made in the management of rheumatic diseases in the past
two decades. The introduction of biologic agents in both adults and children has provided
significant improvements to patient outcomes and led to better quality of life. Moreover …
Purpose of Review
Given the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients.
Recent Findings
Significant advances have been made in the management of rheumatic diseases in the past two decades. The introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment options.
Summary
Since 2012, Janus kinase (JAK) inhibitors (JAKinibs), a novel group of oral small molecule inhibitors, have demonstrated their efficacy in several forms of adult inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). There are hopes that these successes will be transferable to the paediatric population. In the following review, we discuss the development and progress of JAKinibs in this regard.
Springer